Vindesine/cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung
Thirty-eight pretreated patients with primarily resistant [6] or relapsed [32] small-cell lung cancer were treated with a combination of vindesine (3-4 mg/m2) and cisplatin (60-100 mg/m2). Eight patients responded to this therapy with three (8%) complete and five (13%) partial remissions. Minor resp...
Gespeichert in:
| Veröffentlicht in: | Klinische Wochenschrift 1984-08, Vol.62 (16), p.783-786 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 786 |
|---|---|
| container_issue | 16 |
| container_start_page | 783 |
| container_title | Klinische Wochenschrift |
| container_volume | 62 |
| creator | Niederle, N Schütte, J Krischke, W Seeber, S Schmidt, C G |
| description | Thirty-eight pretreated patients with primarily resistant [6] or relapsed [32] small-cell lung cancer were treated with a combination of vindesine (3-4 mg/m2) and cisplatin (60-100 mg/m2). Eight patients responded to this therapy with three (8%) complete and five (13%) partial remissions. Minor responses were noted in 12 (32%) additional patients. Chemotherapeutic response was rare in regions of prior irradiation. In the complete remission group survival from start of vindesine/cisplatin therapy lasted 61, 48 and 38 weeks, respectively. In the "less-than-complete-remission" group median survival was 12 weeks. Nausea and vomiting were the prominent side-effects, while only mild to moderate myelosuppression was noticed in most cases. The vindesine/cisplatin combination showed significant activity in heavily pretreated small-cell lung carcinoma. However, the remission rates remain low in this unfavourable condition, which might be due to pronounced chemotherapeutic resistance in previously irradiated areas. |
| doi_str_mv | 10.1007/BF01721778 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF01721778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6090762</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-7d69789023a647403101d493ecc8c42b813b4468708dab152591353db346d7e73</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotVYv3oWchbWTj81kj1qsCgUv6nXJJqmNZD9Itof-e1cqehpm5uHl5SHkmsEdA8DlwxoYcoaoT8icScELJiWckjkAF8X0EOfkIucvgJIjqhmZKagAFZ8T9xE653Po_NKGPEQzho7anW_7ceeTGQ502pOPZsje0T7RIYXWpBAP0zWHPJpupLk1MRbWx0itSTZ0fWtov6VTBI377vOSnG1NzP7qdy7I-_rxbfVcbF6fXlb3m8JyzccCnapQV1NnoyRKEAyYk5Xw1moreaOZaKRUGkE707CSlxUTpXCNkMqhR7Egt8dcm_qck9_Wx7aHmkH9Y6r-NzXBN0d42Detd3_orxrxDS-4Yzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vindesine/cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Niederle, N ; Schütte, J ; Krischke, W ; Seeber, S ; Schmidt, C G</creator><creatorcontrib>Niederle, N ; Schütte, J ; Krischke, W ; Seeber, S ; Schmidt, C G</creatorcontrib><description>Thirty-eight pretreated patients with primarily resistant [6] or relapsed [32] small-cell lung cancer were treated with a combination of vindesine (3-4 mg/m2) and cisplatin (60-100 mg/m2). Eight patients responded to this therapy with three (8%) complete and five (13%) partial remissions. Minor responses were noted in 12 (32%) additional patients. Chemotherapeutic response was rare in regions of prior irradiation. In the complete remission group survival from start of vindesine/cisplatin therapy lasted 61, 48 and 38 weeks, respectively. In the "less-than-complete-remission" group median survival was 12 weeks. Nausea and vomiting were the prominent side-effects, while only mild to moderate myelosuppression was noticed in most cases. The vindesine/cisplatin combination showed significant activity in heavily pretreated small-cell lung carcinoma. However, the remission rates remain low in this unfavourable condition, which might be due to pronounced chemotherapeutic resistance in previously irradiated areas.</description><identifier>ISSN: 0023-2173</identifier><identifier>EISSN: 1432-1440</identifier><identifier>DOI: 10.1007/BF01721778</identifier><identifier>PMID: 6090762</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Small Cell - drug therapy ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Drug Administration Schedule ; Drug Resistance ; Humans ; Lung Neoplasms - drug therapy ; Male ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Prognosis ; Vinblastine - administration & dosage ; Vinblastine - adverse effects ; Vinblastine - analogs & derivatives ; Vindesine</subject><ispartof>Klinische Wochenschrift, 1984-08, Vol.62 (16), p.783-786</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-7d69789023a647403101d493ecc8c42b813b4468708dab152591353db346d7e73</citedby><cites>FETCH-LOGICAL-c282t-7d69789023a647403101d493ecc8c42b813b4468708dab152591353db346d7e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6090762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niederle, N</creatorcontrib><creatorcontrib>Schütte, J</creatorcontrib><creatorcontrib>Krischke, W</creatorcontrib><creatorcontrib>Seeber, S</creatorcontrib><creatorcontrib>Schmidt, C G</creatorcontrib><title>Vindesine/cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung</title><title>Klinische Wochenschrift</title><addtitle>Klin Wochenschr</addtitle><description>Thirty-eight pretreated patients with primarily resistant [6] or relapsed [32] small-cell lung cancer were treated with a combination of vindesine (3-4 mg/m2) and cisplatin (60-100 mg/m2). Eight patients responded to this therapy with three (8%) complete and five (13%) partial remissions. Minor responses were noted in 12 (32%) additional patients. Chemotherapeutic response was rare in regions of prior irradiation. In the complete remission group survival from start of vindesine/cisplatin therapy lasted 61, 48 and 38 weeks, respectively. In the "less-than-complete-remission" group median survival was 12 weeks. Nausea and vomiting were the prominent side-effects, while only mild to moderate myelosuppression was noticed in most cases. The vindesine/cisplatin combination showed significant activity in heavily pretreated small-cell lung carcinoma. However, the remission rates remain low in this unfavourable condition, which might be due to pronounced chemotherapeutic resistance in previously irradiated areas.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Prognosis</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - adverse effects</subject><subject>Vinblastine - analogs & derivatives</subject><subject>Vindesine</subject><issn>0023-2173</issn><issn>1432-1440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQhoMotVYv3oWchbWTj81kj1qsCgUv6nXJJqmNZD9Itof-e1cqehpm5uHl5SHkmsEdA8DlwxoYcoaoT8icScELJiWckjkAF8X0EOfkIucvgJIjqhmZKagAFZ8T9xE653Po_NKGPEQzho7anW_7ceeTGQ502pOPZsje0T7RIYXWpBAP0zWHPJpupLk1MRbWx0itSTZ0fWtov6VTBI377vOSnG1NzP7qdy7I-_rxbfVcbF6fXlb3m8JyzccCnapQV1NnoyRKEAyYk5Xw1moreaOZaKRUGkE707CSlxUTpXCNkMqhR7Egt8dcm_qck9_Wx7aHmkH9Y6r-NzXBN0d42Detd3_orxrxDS-4Yzw</recordid><startdate>19840816</startdate><enddate>19840816</enddate><creator>Niederle, N</creator><creator>Schütte, J</creator><creator>Krischke, W</creator><creator>Seeber, S</creator><creator>Schmidt, C G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19840816</creationdate><title>Vindesine/cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung</title><author>Niederle, N ; Schütte, J ; Krischke, W ; Seeber, S ; Schmidt, C G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-7d69789023a647403101d493ecc8c42b813b4468708dab152591353db346d7e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Prognosis</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - adverse effects</topic><topic>Vinblastine - analogs & derivatives</topic><topic>Vindesine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niederle, N</creatorcontrib><creatorcontrib>Schütte, J</creatorcontrib><creatorcontrib>Krischke, W</creatorcontrib><creatorcontrib>Seeber, S</creatorcontrib><creatorcontrib>Schmidt, C G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Klinische Wochenschrift</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niederle, N</au><au>Schütte, J</au><au>Krischke, W</au><au>Seeber, S</au><au>Schmidt, C G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vindesine/cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung</atitle><jtitle>Klinische Wochenschrift</jtitle><addtitle>Klin Wochenschr</addtitle><date>1984-08-16</date><risdate>1984</risdate><volume>62</volume><issue>16</issue><spage>783</spage><epage>786</epage><pages>783-786</pages><issn>0023-2173</issn><eissn>1432-1440</eissn><abstract>Thirty-eight pretreated patients with primarily resistant [6] or relapsed [32] small-cell lung cancer were treated with a combination of vindesine (3-4 mg/m2) and cisplatin (60-100 mg/m2). Eight patients responded to this therapy with three (8%) complete and five (13%) partial remissions. Minor responses were noted in 12 (32%) additional patients. Chemotherapeutic response was rare in regions of prior irradiation. In the complete remission group survival from start of vindesine/cisplatin therapy lasted 61, 48 and 38 weeks, respectively. In the "less-than-complete-remission" group median survival was 12 weeks. Nausea and vomiting were the prominent side-effects, while only mild to moderate myelosuppression was noticed in most cases. The vindesine/cisplatin combination showed significant activity in heavily pretreated small-cell lung carcinoma. However, the remission rates remain low in this unfavourable condition, which might be due to pronounced chemotherapeutic resistance in previously irradiated areas.</abstract><cop>Germany</cop><pmid>6090762</pmid><doi>10.1007/BF01721778</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0023-2173 |
| ispartof | Klinische Wochenschrift, 1984-08, Vol.62 (16), p.783-786 |
| issn | 0023-2173 1432-1440 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF01721778 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Small Cell - drug therapy Cisplatin - administration & dosage Cisplatin - adverse effects Drug Administration Schedule Drug Resistance Humans Lung Neoplasms - drug therapy Male Middle Aged Neoplasm Recurrence, Local - drug therapy Prognosis Vinblastine - administration & dosage Vinblastine - adverse effects Vinblastine - analogs & derivatives Vindesine |
| title | Vindesine/cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A08%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vindesine/cisplatin%20chemotherapy%20in%20relapsed%20or%20primarily%20resistant%20small-cell%20carcinoma%20of%20the%20lung&rft.jtitle=Klinische%20Wochenschrift&rft.au=Niederle,%20N&rft.date=1984-08-16&rft.volume=62&rft.issue=16&rft.spage=783&rft.epage=786&rft.pages=783-786&rft.issn=0023-2173&rft.eissn=1432-1440&rft_id=info:doi/10.1007/BF01721778&rft_dat=%3Cpubmed_cross%3E6090762%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6090762&rfr_iscdi=true |